Back to Search
Start Over
Is the Importance of Heart Dose Overstated in the Treatment of Non-Small Cell Lung Cancer? A Systematic Review of the Literature
- Source :
- Ann Transl Med
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
-
Abstract
- Purpose Some recent studies have suggested a relationship between cardiac dose and mortality in non-small cell lung cancer (NSCLC), but others have reported conflicting data. The goal of this study was to conduct a systematic review and meta-analysis to provide an evidence-based estimate of the relationship between cardiac dose and mortality in these patients. Methods and Materials A systematic review of MEDLINE (PubMed) and Embase databases (inception to January 2018) was performed according to PRISMA guidelines. Studies that evaluated cardiac dosimetric factors in patients with NSCLC and included outcomes of cardiac events, cardiac mortality, and/or overall survival were identified. Results From 5614 patients across 22 studies, a total of 214 cardiac dosimetric parameters (94 unique) were assessed as possible predictors of cardiac toxicity or death. Assessed predictors included general (eg, mean heart dose [MHD]), threshold-based (eg, heart V5), and anatomic-based (eg, atria, ventricles) dosimetric factors. The most commonly analyzed parameters were MHD, heart V5, and V30. Most studies did not make corrections for multiplicity of testing. For overall survival, V5 was found to be significant on multivariable analysis (MVA) in 1 of 11 studies and V30 in 2 of 12 studies; MHD was not significant in any of 8 studies. For cardiac events, V5 was found to be significant on multivariable analysis in 1 of 2 studies, V30 in 1 of 3 studies, and MHD in 2 of 4 studies. A meta-analysis of the data could not be performed because most negative studies did not report effect estimates. Conclusions Consistent heart dose-volume parameters associated with overall survival of patients with NSCLC were not identified. Multiplicity of testing is a major issue and likely inflates the overall risk of type I errors in the literature. Future studies should specify predictors a priori, correct for multiplicity of testing, and report effect estimates for nonsignificant variables.
- Subjects :
- Adult
Male
Oncology
Cancer Research
medicine.medical_specialty
Lung Neoplasms
Future studies
MEDLINE
Cardiac mortality
Radiation Dosage
030218 nuclear medicine & medical imaging
03 medical and health sciences
0302 clinical medicine
Carcinoma, Non-Small-Cell Lung
Cardiac toxicity
Internal medicine
medicine
Overall survival
Humans
Radiology, Nuclear Medicine and imaging
In patient
Lung cancer
Aged
Aged, 80 and over
Radiation
business.industry
Heart
Middle Aged
Radiation Exposure
medicine.disease
Cardiotoxicity
Editorial Commentary
030220 oncology & carcinogenesis
Multivariate Analysis
Female
Non small cell
business
Subjects
Details
- ISSN :
- 03603016
- Volume :
- 104
- Database :
- OpenAIRE
- Journal :
- International Journal of Radiation Oncology*Biology*Physics
- Accession number :
- edsair.doi.dedup.....76a7efb5524669d009b207171076d31a
- Full Text :
- https://doi.org/10.1016/j.ijrobp.2018.12.044